Key result
Candesartan fails to reduce tau pathology or neuroinflammation in tau-transgenic mice.
Why the study?
Drugs targeting the renin-angiotensin system to reduce blood pressure could potentially delay neurodegenerative disease onset, but their effects on tau-associated pathologies are understudied.
Does chronic treatment with candesartan (5 mg/kg for 6 weeks) reduce tau pathology, neuronal degeneration, and brain inflammation in line 66 P301S tau-transgenic mice?
Does chronic treatment with candesartan (5 mg/kg for 6 weeks) reduce tau pathology, neuronal degeneration, and brain inflammation in line 66 P301S tau-transgenic mice?
Six weeks of oral candesartan treatment at 5 mg/kg did not modify brain tau pathology, angiotensin receptor expression, neuronal density, or astrocyte activation in P301S tau-transgenic (L66) mice.
Answers are grounded in this paper and cite their sources.
Candesartan showed no tau benefit in L66 mice; leaves open whether RAS blockade modifies human tauopathies and requires alternative models.
The aggregation of the microtubule-associated protein tau is a hallmark in many neurodegenerative diseases such as Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Hypertension increases the risk of neurodegenerative diseases, and there is evidence that drugs targeting the renin-angiotensin system (RAS) to reduce blood pressure (BP) could potentially delay neurodegenerative disease onset due to their action on brain RAS. However, the effect of such treatment on pathologies associated with tau are understudied. We have treated three-month old line 66 (L66) tau-transgenic mice expressing the P301S mutation for six weeks with the angiotensin receptor blocker (ARB) candesartan at 5 mg/kg and investigated tau pathology, angiotensin II (Ang II) type 1 receptor (AT1R), Ang II type 2 receptor (AT2R), neurones, microglia, and astrocytes using immunohistochemistry (IHC) and immunoblotting. AT1R and AT2R levels, as well as cortical thickness, number of neurones, GFAP-positive astrocytes and Iba1-positive microglia were all not affected by candesartan treatment. L66 mice had more human tau but less mouse pSer202 tau and total mouse tau, but candesartan treatment did not normalise these differences. Therefore, candesartan administered for six weeks at 5 mg/kg did not lead to a significant reduction of dementia-related pathologies in L66 tau-transgenic mice.
No takes yet. Share an insight, caveat, or question.
Schwab et al. (2026) studied Tauopathy / Frontotemporal dementia (FTD) and Alzheimer's disease (AD) preclinical model (n=50). Candesartan vs. Vehicle (deionised water) orally via gavage (5 mL/kg) was evaluated on Brain tau pathology (HT7 immunoreactivity, pSer202 tau, Tau46, and 7/51 tau levels), angiotensin receptors (AT1R, AT2R), neuronal density (NeuN, cortical thickness), and neuroinflammation (GFAP, Iba1). Candesartan did not reduce human tau pathology, alter AT1R/AT2R levels, or modify neuronal and glial markers in L66 tau-transgenic mice.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: